Showing 1 - 10 of 38
Persistent link: https://www.econbiz.de/10011001592
The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of eltrombopag (GlaxoSmithKline) to submit evidence for the clinical and cost effectiveness of this drug for the treatment of patients with chronic immune or idiopathic thrombocytopenic purpura (ITP), as...
Persistent link: https://www.econbiz.de/10011001721
The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of eltrombopag (GlaxoSmithKline) to submit evidence for the clinical and cost effectiveness of this drug for the treatment of patients with chronic immune or idiopathic thrombocytopenic purpura (ITP), as...
Persistent link: https://www.econbiz.de/10010548287
Persistent link: https://www.econbiz.de/10010484340
Persistent link: https://www.econbiz.de/10004927664
Persistent link: https://www.econbiz.de/10009527974
Background Provision of evidence on costs alongside evidence on the effects of interventions can enhance the relevance of systematic reviews to decision-making. However, patterns of use of economics methods alongside systematic review remain unclear. Reviews of evidence on the effects of...
Persistent link: https://www.econbiz.de/10009440624
Persistent link: https://www.econbiz.de/10003479897
Persistent link: https://www.econbiz.de/10003612044
Persistent link: https://www.econbiz.de/10001775211